ABT

Abbott Laboratories occupies a rare structural position in global healthcare: a company that has systematically shed the highest-margin, highest-risk segments of its former self (branded pharmaceuticals via AbbVie in 2013, the St. Jude Medical integration that reshuffled its cardiac portfolio) and emerged as something the market still struggles to categorize cleanly. Abbott is not a pure-play medical device company. It is not a diagnostics company. It is not a nutritional products company. It is all three, bound together by a strategic logic that only becomes visible when one examines where its pricing power actually resides.

The central analytical question for Abbott in early 2026 is deceptively simple: can a diversified health care equipment and products company sustain above-market growth without the tailwind of pandemic diagnostics revenue, and without the concentrated pricing power that comes with pharmaceutical exclusivity? Abbott's COVID-19 rapid testing business, which surged past $7 billion in annual revenue at its peak in 2021 and 2022, has now largely normalized. The company guided investors toward a post-pandemic baseline, and the market accepted the narrative. But the structural reality beneath the narrative is more interesting than the headline numbers suggest.

The L17X insight is this: Abbott's true competitive advantage is not its product portfolio or its geographic diversification, but its ability to create recurring revenue streams in product categories that historically were transactional. The FreeStyle Libre continuous glucose monitoring (CGM) platform does not merely compete in diabetes care. It transforms a commodity (glucose test strips sold in retail) into a sensor-plus-subscription ecosystem with per-patient annual revenue that is multiples of the legacy product it replaces. This is the playbook Abbott is now attempting to replicate across cardiac rhythm management, structural heart, and even point-of-care diagnostics. The question is whether the playbook transfers, or whether Libre's success was an artifact of a uniquely favorable regulatory and reimbursement window that cannot be reproduced.

Abbott matters now because it sits at the intersection of three structural forces reshaping healthcare: the shift from episodic treatment to continuous monitoring, the global expansion of diagnostic access in emerging markets, and the demographic pressure of aging populations in developed economies. These forces are well understood. What is less understood is how Abbott's organizational architecture, a diversified conglomerate structure that most investors would instinctively discount, may actually be the optimal vehicle for capturing value across all three simultaneously.